JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. Yesterday saw some high-value dealmaking, including one of the biggest acquisitions in recent JPM memory, when Johnson & Johnson snapped up neuro biopharma Intra-Cellular for a cool $14.6 billion.

On the clinical side, we saw GSK shell out just over $1 billion for gastrointestinal cancer specialists IDRx, while Eli Lilly, flush with its Mounjaro cash, paid $2.5 billion for Scorpion Therapeutics.